$BEAM
"I think if there is a general just kind of comment that I have that I think these LNPs are really doing quite well. This is a great delivery modality where we are talking about temporary headache, fever, flush kinds of infusion reactions or lab abnormalities in return for a one-time dose that gets you potentially transformative durable efficacy like we are seeing here. It is a pretty good delivery vehicle. We are quite happy with it."
—John Evans, CEO, this morning throwing shade at analysts who are obsessed with the transient side effects of LNPs at dosing vs the permanent effect of the therapy: being cured of their genetic disease.